Last 3,977 INR
Change Today 0.00 / 0.00%
Volume 0.0
BOOT On Other Exchanges
Symbol
Exchange
Natl India
As of 6:05 AM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

abbott india ltd (BOOT) Snapshot

Open
4,065
Previous Close
3,997
Day High
4,065
Day Low
3,930
52 Week High
01/2/15 - 4,444
52 Week Low
02/3/14 - 1,590
Market Cap
84.5B
Average Volume 10 Days
3.7K
EPS TTM
93.39
Shares Outstanding
21.2M
EX-Date
07/23/14
P/E TM
42.6x
Dividend
23.00
Dividend Yield
0.58%
Current Stock Chart for ABBOTT INDIA LTD (BOOT)

Related News

No related news articles were found.

abbott india ltd (BOOT) Related Businessweek News

No Related Businessweek News Found

abbott india ltd (BOOT) Details

Abbott India Limited operates as a pharmaceutical and healthcare company in India. The company offers pharmaceutical products for various therapeutic areas, such as women's health, gastroenterology, neurology, thyroid, diabetes and urology, pain management, vitamins, anti-infectives, allergies, anti-coagulants, cardiology, and immunology, as well as other therapy areas, including anesthesia and critical care, virology, endocrinology, and neonatology. Abbott India Limited markets its products primarily through a network of 30 distribution points, catering to approximately 4,900 stockists and 150,000 retail outlets. The company was incorporated in 1944 and is headquartered in Mumbai, India. Abbott India Limited is a subsidiary of Abbott Capital India Ltd.

2,766 Employees
Last Reported Date: 07/7/14
Founded in 1944

abbott india ltd (BOOT) Top Compensated Officers

Managing Director, Executive Director, Member...
Total Annual Compensation: 41.9M
Director of Legal & Secretarial, Whole - Time...
Total Annual Compensation: 10.7M
Compensation as of Fiscal Year 2014.

abbott india ltd (BOOT) Key Developments

Abbott India Limited Announces Availability of its Diagnostic Platform Known as IRIDICA in Europe and Other CE-Mark Recognized Countries

Abbott India Limited has announced the availability of its diagnostic platform known as IRIDICA in Europe and other CE-Mark recognized countries. The new platform can identify more than 1,000 infection-causing pathogens in less than six hours, versus the current standard of care (culture-based testing), which can take days. By identifying the cause of infections such as bacteria, viruses or fungi sooner, doctors can improve care for the critically ill. IRIDICA uses a combination of sophisticated testing technologies known as Polymerase Chain Reaction/Electrospray Ionization Mass Spectrometry (PCR/ESI-MS) to rapidly identify infection-causing pathogens directly from a patient's sample, without the need for culture. According to Abbott's RApid Diagnosis of Infections in the CriticAlly IlL (RADICAL) study results, the technology was able to detect pathogens when the current standard of care did not. In the study, after retrospectively comparing the results of Abbott's technology versus culture, an independent panel of physicians reported it would have prescribed a different course of treatment in nearly 60% of cases evaluated. Additionally, analysis of the study results suggested that Abbott's technology could help lower associated health care costs by 30% and reduce hospital stays for people with serious infections by up to eight days.

Abbott India Limited Reports Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2014

Abbott India Limited reported unaudited standalone earnings results for the second quarter and six months ended September 30, 2014. For the quarter, net sales/income from operation was INR 57.542 million against INR 44.473 million a year ago. Profit from operation before other income and finance cost was INR 8.358 million against INR 6.123 million a year ago. profit from ordinary activities before tax was INR 9.578 million against INR 6.817 million a year ago. profit from ordinary activities after tax was INR 6.374 million or INR 30.00 per basic and diluted share against INR 4.519 million or INR 21.27 per basic and diluted share a year ago. For the six months, net sales/income from operation was INR 109.433 million against INR 87.441 million a year ago. Profit from operation before other income and finance cost was INR 15.018 million against INR 9.892 million a year ago. profit from ordinary activities before tax was INR 17.197 million against INR 11.255 million a year ago. profit from ordinary activities after tax was INR 11.467 million or INR 53.96 per basic and diluted share against INR 7.490 million or INR 35.25 per basic and diluted share a year ago.

Abbott India Limited to Report Q2, 2015 Results on Nov 11, 2014

Abbott India Limited announced that they will report Q2, 2015 results on Nov 11, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BOOT:IN 3,976.75 INR 0.00

BOOT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cadila Healthcare Ltd 1,647 INR 0.00
Pfizer Ltd/India 2,140 INR 0.00
Piramal Enterprises Ltd 834.95 INR 0.00
Ranbaxy Laboratories Ltd 706.60 INR 0.00
Sanofi India Ltd 3,450 INR 0.00
View Industry Companies
 

Industry Analysis

BOOT

Industry Average

Valuation BOOT Industry Range
Price/Earnings 41.3x
Price/Sales 4.0x
Price/Book 9.5x
Price/Cash Flow 38.4x
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBOTT INDIA LTD, please visit www.abbott.co.in. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.